| Effect of ATP-sensitive potassium channel inhibition on resting coronary vascular responses in humans. | |
| | |
MedLine Citation:
|
PMID: 11834717 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Experimental data suggest that vascular ATP-sensitive potassium (K(ATP)) channels regulate coronary blood flow (CBF), but their role in regulating human CBF is unclear. We sought to determine the contribution of K(ATP) channels to resting conduit vessel and microvascular function in the human coronary circulation. Twenty-five patients (19 male/6 female, aged 56 +/- 12 years) were recruited. Systemic and coronary hemodynamics were assessed in 20 patients before and after K(ATP) channel inhibition with graded intracoronary glibenclamide infusions (4, 16, and 40 microg/min), in an angiographically smooth or mildly stenosed coronary artery following successful elective percutaneous coronary intervention to another vessel. Coronary blood velocity was measured with a Doppler guidewire and CBF calculated. Adenosine-induced hyperemia was determined following bolus intracoronary adenosine injection (24 microg). Time control studies were undertaken in 5 patients. Compared with vehicle infusion (0.9% saline), glibenclamide reduced resting conduit vessel diameter from 2.5 +/- 0.1 to 2.3 +/- 0.1 mm (P<0.01), resting CBF by 17% (P=0.05), and resting CBF corrected for rate pressure-product by 18% (P=0.01) in a dose-dependent manner. A corresponding 24% increase in coronary vascular resistance was noted at the highest dose (P<0.01). No alteration to resting CBF was noted in the time control studies. Glibenclamide reduced peak adenosine-induced hyperemia (P=0.01) but did not alter coronary flow reserve. Plasma insulin increased from 5.6 +/- 1.2 to 7.6 +/- 1.3 mU/L (P=0.02); however, plasma glucose was unchanged. Vascular K(ATP) channels are involved in the maintenance of basal coronary tone but may not be essential to adenosine-induced coronary hyperemia in humans. |
| | |
Authors:
|
H M Omar Farouque; Stephen G Worthley; Ian T Meredith; R Andrew P Skyrme-Jones; Michael J Zhang |
Related Documents
:
|
3888437 - Coronary flow regulation in patients with ischemic heart disease: release of purines an... 1984887 - Coronary vasodilator reserve. comparison of the effects of papaverine and adenosine on ... 14623767 - Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. 1706807 - Inhibition of coronary artery thrombosis by sin-1, a donor of nitric oxide. 8697827 - The diagnosis of pericardial effusion and cardiac tamponade by 12-lead ecg. a technolog... 12957757 - Indium-111 monoclonal antimyosin cardiac scintigraphy in suspected acute myocarditis: e... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Circulation research Volume: 90 ISSN: 1524-4571 ISO Abbreviation: Circ. Res. Publication Date: 2002 Feb |
Date Detail:
|
Created Date: 2002-02-08 Completed Date: 2002-02-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0047103 Medline TA: Circ Res Country: United States |
Other Details:
|
Languages: eng Pagination: 231-6 Citation Subset: IM |
Affiliation:
|
Centre for Heart and Chest Research, Monash Medical Centre and Monash University, Melbourne, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenosine
/
pharmacology Adenosine Triphosphate / metabolism* Blood Flow Velocity / drug effects Blood Glucose / drug effects Coronary Angiography Coronary Artery Disease / complications, metabolism* Coronary Circulation / drug effects Coronary Vessels / drug effects, metabolism* Diabetes Mellitus, Type 2 / complications, metabolism Dose-Response Relationship, Drug Electrocardiography / drug effects Female Glyburide / administration & dosage, adverse effects Humans Hypoglycemic Agents / administration & dosage, adverse effects Infusions, Intra-Arterial Insulin / blood Male Microcirculation* / drug effects Middle Aged Potassium Channel Blockers Potassium Channels / metabolism* Vascular Patency / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Potassium Channel Blockers; 0/Potassium Channels; 10238-21-8/Glyburide; 11061-68-0/Insulin; 56-65-5/Adenosine Triphosphate; 58-61-7/Adenosine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tissue engineering of a differentiated cardiac muscle construct.
Next Document: Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities.